Brigitte Kolb

6.6k citations

25 papers · 728 indexed · h-index 9

Impact in

Hematology top 2%
- Multiple Myeloma Research and Treatments
Genetics top 5%
- Glioma Diagnosis and Treatment

Papers in ⓘ

Hematology 17
- Multiple Myeloma Research and Treatments 16
- Chronic Myeloid Leukemia Treatments 4
Genetics 7
- Chronic Lymphocytic Leukemia Research 5

Co-authors: Xavier Leleu (12 shared papers)Philippe Moreau (13 shared papers)Murielle Roussel (9 shared papers)Denis Caillot (7 shared papers)Thierry Façon (9 shared papers)Michel Attal (9 shared papers)Cyrille Hulin (6 shared papers)Lotfi Benboubker (7 shared papers)
Journals: Blood (10 papers)Journal of Clinical Oncology (8 papers)HemaSphere (1 paper)Amyloid (1 paper)Bone Marrow Transplantation (1 paper)
Partner nations: France United States Switzerland

In The Last Decade

Brigitte Kolb

25 papers receiving 702 citations

Peers

Countries citing papers authored by Brigitte Kolb

Since Specialization

Citations

This map shows the geographic impact of Brigitte Kolb's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brigitte Kolb with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brigitte Kolb more than expected).

Fields of papers citing papers by Brigitte Kolb

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brigitte Kolb. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brigitte Kolb. The network helps show where Brigitte Kolb may publish in the future.

Co-authors

The 25 scholars most cited alongside Brigitte Kolb, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Brigitte Kolb Line = papers co-authored together Brigitte Kolb links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 25 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p) Journal of Clinical Oncology ·Hervé Avet‐Loiseau, Xavier Leleu, Murielle Roussel, Philippe Moreau, Catherine Guérin‐Charbonnel, Denis Caillot, Gérald Marit, Lotfi Benboubker, Laurent Voillat, Claire Mathiot, Brigitte Kolb, Margaret Macro, L. Campion, Marc Wetterwald, Anne‐Marie Stoppa, Cyrille Hulin, Thierry Façon, Michel Attal, Stéphane Minvielle, Jean‐Luc Harousseau	2010	298
2	Intensive Chemotherapy Followed by Hematopoietic Stem-Cell Rescue for Refractory and Recurrent Primary CNS and Intraocular Lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire Journal of Clinical Oncology ·Carole Soussain, Khê Hoang‐Xuan, Luc Taillandier, Emmanuelle Fourme, Sylvain Choquet, Francis Witz, Olivier Casasnovas, Brigitte Dupriez, Bertrand Souleau, Anne‐Laure Taksin, Christian Gisselbrecht, Arnaud Jaccard, Antonio Omuro, Marc Sanson, Maud Janvier, Brigitte Kolb, J.M. Zini, Véronique Leblond	2008	214
3	Phase 1/2 study of carfilzomib plus melphalan and prednisone in patients aged over 65 years with newly diagnosed multiple myeloma Blood ·Philippe Moreau, Brigitte Kolb, Michel Attal, Denis Caillot, Lotfi Benboubker, Mourad Tiab, Cyrille Touzeau, Xavier Leleu, Murielle Roussel, Carine Chaleteix, Lucie Planche, Anne Chiffoleau, June Fortin, Hervé Avet‐Loiseau, Jean–Yves Mary, Cyrille Hulin, Thierry Façon	2015	39
4	Effects of early postoperative chemotherapy on wound healing. PubMed ·Brigitte Kolb, Richard E. Buller, Joseph P. Connor, Philip J. DiSaia, M L Berman	1992	34
5	Susceptibility of malignant and normal target cells to the cytotoxic action of bone-marrow macrophages activated in vitro with the macrophage cytotoxicity factor (MCF) Cellular Immunology ·Marie‐Luise Lohmann‐Matthes, Brigitte Kolb, H.G. Meerpohl	1978	22
6	Autologous transplantation in CLL patients with B and C Binet stages: final results of the prospective randomized GOELAMS LLC 98 trial Bone Marrow Transplantation ·A. Brion, Beatrice Mahé, Brigitte Kolb, B. Audhuy, P Colombat, Hervé Maisonneuve, C. Foussard, Alain Bureau, C Ferrand, Jean‐François Lesesve, Massimiliano Del Bene, Pierre Feugier, (unknown)	2011	19
7	Phase I/II study of carfilzomib plus melphalan-prednisone (CMP) in elderly patients with de novo multiple myeloma. Journal of Clinical Oncology ·Brigitte Kolb, Cyrille Hulin, Denis Caillot, Lotfi Benboubker, Mourad Tiab, Nicolas Blin, Xavier Leleu, Murielle Roussel, Michel Attal, Thierry Façon, Philippe Moreau	2012	14
8	Étude comparative du dosage des chaînes légères libres d’immunoglobulines par technique Freelite™ (The Binding Site) et N Latex FLC (Siemens) Annales de biologie clinique ·Nathalie Schneider, Alain Wynckel, Brigitte Kolb, Émilie Sablon, Philippe Gillery, François‐Xavier Maquart	2013	10
9	Comparative analysis of immunoglobulin free light chains quantification by Freelite™ (The Binding Site) and N Latex FLC (Siemens) methods Annales de biologie clinique ·Nathalie Schneider, Alain Wynckel, Brigitte Kolb, Emilie Sablon, Philippe Gillery, François‐Xavier Maquart	2013	9
10	Treatment of Myeloma Cast Nephropathy (MCN): A Randomized Trial Comparing Intensive Haemodialysis (HD) with High Cut-Off (HCO) or Standard High-Flux Dialyzer in Patients Receiving a Bortezomib-Based Regimen (the MYRE Study, by the Intergroupe Francophone du Myélome (IFM) and the French Society of Nephrology (SFNDT)) Blood ·Frank Bridoux, Brigitte Pegourié, Karine Augeul-Meunier, Bruno Royer, Bertrand Joly, Thierry Lamy, Brigitte Kolb, Lofti Benboubker, Bertrand Arnulf, Arnaud Jaccard, Sylvie Chevret, Jean‐Paul Fermand	2016	8
11	Effect of CMP, carfilzomib (CFZ) plus melphalan-prednisone (MP), on response rates in elderly patients (pts) with newly diagnosed multiple myeloma (NDMM): Results of a phase (Ph) I/II trial. Journal of Clinical Oncology ·Cyrille Touzeau, Brigitte Kolb, Cyrille Hulin, Denis Caillot, Lotfi Benboubker, Mourad Tiab, Xavier Leleu, Murielle Roussel, Carine Chaleteix, Michel Attal, Thierry Façon, Philippe Moreau	2013	8
12	Intensive Chemotherapy Followed by Hematopoietic Stem Cell Rescue for Refractory or Recurrent Primary Central Nervous System (PCNSL) or Intra Ocular Lymphoma (IOL). Results of a Multicentric Phase II Study. Blood ·Carole Soussain, Khê Hoang‐Xuan, Luc Taillandier, Olivier Casasnovas, Brigitte Dupriez, Anne‐Laure Taksin, Bertrand Souleau, Brigitte Kolb, Arnaud Jaccard, Jean‐Marc Zini, Sylvain Choquet, Francis Witz, Maud Janvier, Véronique Leblond	2006	6
13	Preliminary Results of a Prospective Randomized Study Comparing First Line Conventional Therapy Versus High Dose Therapy with Autologous CD34+ Purified Progenitor Cell Support in B CLL Patients with B and C Binet Stages: The GOELAMS LLC98 Study. Blood ·Annie Brion, Beatrice Mahé, Brigitte Kolb, Bernard Audhuy, Philippe Colombat, HervÉ Maisoneuve, Charles Foussard, Alain Bureau, Pierre Feugier	2005	6
14	Evolving Treatment Trends in Relapsed/Refractory Multiple Myeloma (RRMM) in Europe from 2016 to 2018: Analysis of a Multi-National Survey Blood ·Maximilian Merz, Isabelle Vande Broek, Manuel Pérez, Brigitte Kolb, Argiris Symeonidis, Emmanouil Nikolousis, Athanasios Zomas, Francisco Javier Blanco González, Lenka Kellermann, Hartmut Goldschmidt	2019	5
15	Bendamustine, Bortezomib and Dexamethasone (BVD) in Elderly Patients with Multiple Myeloma in First Relapse: Updated Results of the Intergroupe Francophone Du Myelome (IFM) 2009-01 Trial Blood ·Philippe Rodon, Cyrille Hulin, Brigitte Pegourié, Mourad Tiab, Bruno Anglaret, Lotfi Benboubker, Henry Jardel, Olivier Decaux, Brigitte Kolb, Murielle Roussel, Laurent Garderet, Xavier Leleu, Olivier Fitoussi, Carine Chaleteix, Philippe Casassus, Pascal Lenain, Philippe Moreau, Marie Odile Petillon, Claire Mathiot, Hervé Avet‐Loiseau	2012	5
16	Autologous Stem Cell Transplantation (ASCT) Versus Oral Melphalan and High-Dose Dexamethasone In Patients with AL (Primary) Amyloidosis: Long Term Follow-up of the French Multicentric Randomized Trial Blood ·Arnaud Jaccard, Véronique Leblond, Bruno Royer, Xavier Leleu, Richard Delarue, Brigitte Kolb, Éric Deconinck, Aspasia Stamatoullas, Paul Coppo, Bertrand Arnulf, Olivier Hermine, Philippe Moreau, Jean Paul Fermand	2010	5
17	Carfilzomib PLUS Melphalan and Prednisone (CMP) Is A Promising Combination Therapy For The Treatment Of Elderly Patients With NEWLY Diagnosed Multiple Myeloma: Results Of A PHASE I/II Trial In 68 CASES Blood ·Philippe Moreau, Brigitte Kolb, Cyrille Hulin, Denis Caillot, Lotfi Benboubker, Mourad Tiab, Cyrille Touzeau, Xavier Leleu, Murielle Roussel, Carine Chaleteix, Michel Attal, Thierry Façon	2013	5
18	PF598 STEM CELL YIELD AND TRANSPLANTATION IN TRANSPLANT‐ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS RECEIVING DARATUMUMAB + BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE (D‐VTD): PHASE 3 CASSIOPEIA STUDY HemaSphere ·Cyrille Hulin, Philippe Moreau, Michel Attal, Karim Belhadj, Lotfi Benboubker, Denis Caillot, Thierry Façon, Laurent Garderet, F. Kuhnowski, A. M. Stoppa, Brigitte Kolb, Mourad Tiab, Pieter Sonneveld, K.‐S. Jie, Matthijs Westerman, Lixia Pei, Tobias Kampfenkel, Carla de Boer, Jessica Vermeulen, N. W. van de Donk	2019	4
19	Effectiveness of second-line treatment in AL amyloidosis patient's refractory to M-Dex Amyloid ·Amélie Penot, J. Abraham, Houria Debarri, Éstelle Desport, Claire Aguilar, David Lavergne, F. Auroy, Xavier Leleu, A. Goldstein, Brigitte Kolb, Frank Bridoux, Jean‐Paul Fermand, V. Leblond, A. Jaccard	2011	3
20	Stem cell (SC) yield and transplantation results from transplant-eligible newly diagnosed multiple myeloma (TE NDMM) patients (pts) receiving daratumumab (DARA) + bortezomib/thalidomide/dexamethasone (D-VTd) in the phase 3 CASSIOPEIA study. Journal of Clinical Oncology ·Cyrille Hulin, Philippe Moreau, Michel Attal, Karim Belhadj, Lotfi Benboubker, Denis Caillot, Thierry Façon, Laurent Garderet, Frédérique Kuhnowski, Anne‐Marie Stoppa, Brigitte Kolb, Mourad Tiab, Pieter Sonneveld, Kon‐Siong G. Jie, Matthijs Westerman, Lixia Pei, Tobias Kampfenkel, Carla de Boer, Jessica Vermeulen, Niels W.C.J. van de Donk, (unknown)	2019	3

About Brigitte Kolb

Brigitte Kolb is a scholar working on Hematology, Genetics, Oncology, Pathology and Forensic Medicine and Molecular Biology, having authored 25 papers that have together received 728 indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (16 papers), Cancer Treatment and Pharmacology (7 papers), Protein Degradation and Inhibitors (6 papers), Chronic Lymphocytic Leukemia Research (5 papers), Amyloidosis: Diagnosis, Treatment, Outcomes (5 papers), Lymphoma Diagnosis and Treatment (4 papers), Chronic Myeloid Leukemia Treatments (4 papers) and Peptidase Inhibition and Analysis (3 papers). The work is most often cited by research in Hematology (426 citations), Genetics (208 citations), Neurology (214 citations), Pathology and Forensic Medicine (243 citations) and Oncology (238 citations). Brigitte Kolb has collaborated with scholars based in France, United States and Switzerland. Frequent co-authors include Xavier Leleu, Philippe Moreau, Murielle Roussel, Denis Caillot, Thierry Façon, Michel Attal, Cyrille Hulin, Lotfi Benboubker, Hervé Avet‐Loiseau and Jean‐Luc Harousseau. Their work appears in journals such as Blood, Journal of Clinical Oncology, HemaSphere, Amyloid and Bone Marrow Transplantation.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact